- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04565522
Transmission of COVID-19 Virus Among Patients and Staff in Dialysis Centers (DIAL-COVID-19)
Transmission of COVID-19 Among Patients and Health Personnel in Dialysis Centers: a Cohort Prospective Study (DIAL-COVID-19)
Patients on dialysis are at risk for several infectious diseases, since they have reduced immunological and have to regularly attend dialysis centres even if a pandemic is going on. Dialysis patients and healthcare professionals of dialysis centres can become infected one with the other. The incident risk of COVID-19 in dialysis centres is still unknown.
Given the challenges of an early diagnosis of COVID-19, the likely transmission with outbreaks, the possibility of reciprocal transmission of the infection among patients and healthcare professionals, the frequent clinical severity of COVID-19 in dialysis patients because of the coexistence of several comorbidities, CONTACT TRACING could be an effective and efficient tool to contrast COVID-19 spreading in dialysis centres.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients on dialysis are at risk for several infectious diseases, since they have reduced immunological and have to regularly attend dialysis centres from once to thrice a week depending on their residual renal function even if a pandemic is going on.
Dialysis patients and healthcare professionals of dialysis centres can become infected one with the other.
The incident risk of COVID-19 in dialysis centres is still unknown. Given the challenges of an early diagnosis of COVID-19, the likely transmission with outbreaks, the possibility of reciprocal transmission of the infection among patients and healthcare professionals, the frequent clinical severity of COVID-19 in dialysis patients because of the coexistence of several comorbidities, CONTACT TRACING could be an effective and efficient tool to contrast COVID-19 spreading in dialysis centres. This modality keeps trace of the contacts the new COVID-19 case have had and allow the identification of other possible cases in that outbreak
Contact tracing is the key tool to detect and trace COVID-19 cases among patients and health care professionals, i.e. the space-time mapping of the contacts among these two categories:
- Daily for healthcare professionals
- At every dialysis session for haemodialysis patients
- At every hospital visit for patients on peritoneal dialysis
Maximum follow will be up to 12 months excepting in those patients who develop a COVID-19-related clinically significant event:
- Diagnosis of symptomatic COVID-19 with or without hospitalisation
- Respiratory insufficiency with the need of CPAP or mechanical ventilation
- Death associated or related to COVID-19
In the participating centres, the enrolment of patients and healthcare professionals will be prospective, progressive and competitive till the number of cases of COVD-19 will reach 200 subjects. If study participation will be 10% and COVID-19 will be taken by 4% of the patients with no prior exposure to COVID-19, we can estimate to enrol 5000 subjects (dialysis patients and healthcare professionals) over a period of 12 months in 50-150 centres. The length of the enrolment period of 6-12 months will depend also on future evolution of the pandemic in the Italian regions that have not been massively hit by the infection.
Study data will be stored on a web-database, which will be created on purpose. Privacy protection of patients and health care professionals will be pursued and granted by anonymous data collection.
Given the longitudinal and prospective design of the study, Kaplan-Meier curves will be used to describe the incidence of COVID-19 infection and the survival of dialysis patients and their healthcare professionals.
Cox multivariate analysis will be used to:
- Estimate the incidence, morbidity and mortality of COVID-19 in the two categories
- Estimate predictors and/or confounders associated with the incidence of the three study outcomes (infection, morbidity and mortality)
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Simeone Andrulli, MD
- Phone Number: +393472217802
- Email: simeone.andrulli@statgate.it
Study Locations
-
-
-
Catania, Italy
- Cannizzaro
-
Catanzaro, Italy
- AOU Mater Domini
-
Firenze, Italy
- AOU Careggi
-
Foggia, Italy
- Policlinico
-
Mazara Del Vallo, Italy
- CEM-Mazara
-
Nuoro, Italy
- Osp. San Francesco
-
Pescia, Italy
- SOS Nefrologia di Pescia
-
Prato, Italy
- Ospedale di Santo Stefano
-
Roma, Italy
- Ambulatorio Dialisi di Tivoli
-
Roma, Italy
- Geramed Srl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
- Patients on haemodialysis
- Patients on peritoneal dialysis
- Healthcare professionals in charge of dialysis patients
Description
Inclusion Criteria:
- All the patients on haemodialysis or peritoneal dialysis giving their consent to participate
- All healthcare professionals in charge of dialysis patients giving their consent to participate
Exclusion Criteria:
- Dialysis patients or healthcare professionals who already have had Covid-19
- Patients with kidney transplant
- Patients with acute kidney injury (AKI) or on dialysis for less than 3 months
- Life expectancy lower than 6 months
- Patients already enrolled in other clinical trials
- Absence of the consent to participate
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Hemodialysis or peritoneal dialysis patients
Hemodialysis or peritoneal dialysis Covid negative patients
|
Prospective observation until one year follow-up
|
dialysis staff healthcare professionals
dialysis staff Covid negative healthcare professionals
|
Prospective observation until one year follow-up
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
incident risk of COVID-19 infection
Time Frame: 1 year
|
incident risk of COVID-19 infection in dialysis patients and in related dialysis healthcare professionals
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the morbidity of COVID-19
Time Frame: 1 year
|
Evaluate the morbidity (hospitalisation rate) of COVID-19 in the two subject categories
|
1 year
|
Evaluate the mortality of COVID-19
Time Frame: 1 year
|
Evaluate the mortality rate of COVID-19 in the two subject categories
|
1 year
|
Estimate the predictive role of comorbidities, inflammation indexes and therapy on the hospitalisation rate
Time Frame: Three months
|
Estimate the predictive role of comorbidities, inflammation indexes and therapy on the hospitalisation rate in the three months after COVID-19 diagnosis
|
Three months
|
Estimate the predictive role of comorbidities, inflammation indexes and therapy on the mortality rate
Time Frame: Three months
|
Estimate the predictive role of comorbidities, inflammation indexes and therapy on the mortality rate in the three months after COVID-19 diagnosis
|
Three months
|
Evaluate the infective role of dialysis staff towards patients
Time Frame: 1 year
|
Evaluate the infective role of dialysis staff towards patients over one year follow-up
|
1 year
|
Evaluate the infective role of patients towards dialysis staff
Time Frame: 1 year
|
Evaluate the infective role of patients towards dialysis staff over one year follow-up
|
1 year
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DIAL-COVID-19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on Prospective observation
-
University of BergenEuropean Society of Intensive Care MedicineCompletedCritical Illness | Old Age; Debility | SurvivalNorway
-
Europainclinics z.ú.University Hospital Bratislava; Slovak Academy of Sciences; R-CLINIC s.r.o.; Faculty...Recruiting
-
Fondation Ophtalmologique Adolphe de RothschildRecruitingIschemic Stroke | ThrombectomyFrance
-
Emilio BouzaElena Reigadas Ramirez; Patricia Muñoz GarcíaUnknownClostridium Difficile InfectionSpain
-
Sun Yat-sen UniversityActive, not recruitingStage III Non-small-cell Lung CancerChina
-
University of Maryland, BaltimoreUnited States Department of DefenseNot yet recruitingHypoxia | Hypothermia | Mountain Sickness
-
Samsung Medical CenterCompletedNon-Hodgkin T-cell LymphomaKorea, Republic of
-
IHF GmbH - Institut für HerzinfarktforschungMinisterium für Soziales, Arbeit, Gesundheit und Demografie des Landes Rheinland-PfalzCompleted
-
Assiut UniversityRecruitingMullerian Duct AnomaliesEgypt
-
St. Justine's HospitalCanadian Institutes of Health Research (CIHR)RecruitingPediatric Acute Respiratory Distress SyndromeCanada